TH86601A - Pharmaceutical components include (E) -7- (4- (4- fluorophenyl) -6-isopropyl-2- (methyl (methyl sulfonyl) amino) pyrimidin-5 - il) -3 R., 5S) -3,5-dihydroxyapat-6-enoic acid - Google Patents
Pharmaceutical components include (E) -7- (4- (4- fluorophenyl) -6-isopropyl-2- (methyl (methyl sulfonyl) amino) pyrimidin-5 - il) -3 R., 5S) -3,5-dihydroxyapat-6-enoic acidInfo
- Publication number
- TH86601A TH86601A TH1002928A TH0001002928A TH86601A TH 86601 A TH86601 A TH 86601A TH 1002928 A TH1002928 A TH 1002928A TH 0001002928 A TH0001002928 A TH 0001002928A TH 86601 A TH86601 A TH 86601A
- Authority
- TH
- Thailand
- Prior art keywords
- methyl
- fluorophenyl
- isopropyl
- amino
- enoic acid
- Prior art date
Links
- -1 methyl (methyl sulfonyl) amino Chemical group 0.000 title claims abstract 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 title claims abstract 4
- 239000002253 acid Substances 0.000 title claims abstract 4
- 239000005426 pharmaceutical component Substances 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 125000002091 cationic group Chemical group 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000000306 component Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims 1
- 229960001545 hydrotalcite Drugs 0.000 claims 1
- 229910001701 hydrotalcite Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 1
Abstract
DC60 (08/01/51) การประดิษฐ์นี้เกี่ยวข้องกับสารผสมเชิงเภสัชกรรม และโดยเฉพาะอย่างยิ่งเกี่ยวข้องกับ สารผสมเชิงเภสัชกรรมที่มี (E)-7-[4-(4-ฟลูออโรเฟนิล)-6-ไอโซโพรพิล-2-[เมธิล(เมธิลซัลโฟนิล) อะมิโน] ไพริมิดิน -5-อิล]-(3R,5S)3,5-ไดไฮดรอกซิเฮพท์-6-อีโนอิคแอซิด หรือเกลือของสารเหล่านี้ ซึ่งเป็นที่ยอมรับในเชิงเภสัชกรรมในการเป็นส่วนประกอบที่แสดงฤทธิ์ และเกลืออนินทรีย์ที่ แคทไอออน คือ ชนิดหลายเวเลนท์ การประดิษฐ์นี้เกี่ยวข้องกับสารผสมเชิงเภสัชกรรม และโดยเฉพาะอย่างยิ่งเกี่ยวข้องกับ สารผสมเชิงเภสัชกรรมที่มี (E)-7-[4-(4-ฟลูออโรเฟนิล)-6-ไอโซโพรพิล-2-[เมธิล(เมธิลซัลโฟนิล) อะมิ โน] ไพริมิดิน -5-อิล]-(3R,5S)3,5-ไดไฮดรอกซิเฮพท์-6-อีโนอิคแอซิด หรือเกลือของสารเหล่านี้ซึ่งเป็น ที่ยอมรับในเชิงเภสัชกรรมในการเป็นส่วนประกอบที่แสดงฤทธิ์ และเกลืออนินทรีย์ที่แคทไอออนคือ ชนิดหลายเวเลนท์ สิทธิบัตรยา DC60 (08/01/51) This invention relates to pharmaceutical mixtures. And especially related to Pharmaceutical mixtures containing (E) -7- (4- (4- fluorophenyl) -6-isopropyl-2- (methyl (methyl sulfonyl) amino) pyrimite) Soil-5-il) - (3R, 5S) 3,5-dihydroxylate-6-enoic acid. Or the salts of these substances Which is accepted in a pharmaceutical field as a active ingredient And the cationic inorganic salt is a multi-valent type. The invention involved pharmaceutical mixtures. And especially related to Pharmaceutical mixtures containing (E) -7- (4- (4- fluorophenyl) -6-isopropyl-2- (methyl (methyl sulfonyl) amino) pyrimite) Soil-5-il) - (3R, 5S) 3,5-dihydroxylate-6-enoic acid. Or the salts of these substances which are Pharmacy acceptable as a active ingredient. And the inorganic salt that the cation is Multi-valent type drug patent
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH86601A true TH86601A (en) | 2007-09-20 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR6687A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INHIBITORS OF HMG COA REDUCTASA | |
| BR0213242A (en) | Compound or a salt or solvate thereof, compound and physiologically acceptable acid addition salts thereof, pharmaceutical composition, method of treating one or more disorders, use of a compound, and process of preparing a compound | |
| CY1109756T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING Crystalline Salts 7- [4- (4-Fluorophenyl) -6-Isopropyl-2- [Methyl (Methylsulfonyl) -5-5-yl] -3-5-amino-3-yl] -5-y -NIGHT ACID | |
| BR0109650A (en) | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | |
| BRPI0215312B8 (en) | compound, use of a compound, pharmaceutical composition, and process for preparing a compound | |
| JO3404B1 (en) | A liquid pharmaceutical formulation containing erythropoietin derivatives | |
| BRPI0116237B8 (en) | "sulfamide compound, pharmaceutical composition containing it and its use as an endothelin receptor antagonist drug". | |
| NO20040547L (en) | Amino-phthalazine derivatives active as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing them. | |
| IT8947701A0 (en) | PIPERAZINE DERIVATIVE OR ITS SALT, PROCEDURE FOR PRODUCING IT AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS IT AS AN ACTIVE INGREDIENT | |
| BR9906735A (en) | Aqueous liquid pharmaceutical composition | |
| CY1110395T1 (en) | HYDROPYRIDINE PRODUCERS ACID ADDITIONAL SALTS | |
| BR0213842A (en) | Quinazoline derivative or a pharmaceutically acceptable salt thereof, process for preparing the same, pharmaceutical composition, and use of the quinazoline derivative or pharmaceutically acceptable salt thereof | |
| HUP0104828A3 (en) | Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation | |
| DE50313292D1 (en) | Revealing liposomes and their use for the pulmonary application of drugs | |
| BR0013009A (en) | Use of cgrp antagonists and cgrp release inhibitors to combat menopausal hot jets | |
| AR035889A1 (en) | CITRATE OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] HEXADECA-2 (11), 3,5,7,9- PENTAENE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE DEVELOPMENT OF MEDICINES | |
| DE60103978D1 (en) | PRODUCT DERIVATIVES FOR COMBATING CANCER AND VIRUS-RELATED DISEASES | |
| EP1254658A4 (en) | DRUGS | |
| TW200420557A (en) | Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient | |
| DE50006898D1 (en) | AQUEOUS MEDICINAL FORMULATION OF MOXIFLOXACIN OR SALTS THEREOF | |
| ATE295183T1 (en) | AGENTS FOR RELIEVING ITCH CONTAINING PGD2 ANTAGONISTS | |
| BR0103048A (en) | N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists | |
| TH86601A (en) | Pharmaceutical components include (E) -7- (4- (4- fluorophenyl) -6-isopropyl-2- (methyl (methyl sulfonyl) amino) pyrimidin-5 - il) -3 R., 5S) -3,5-dihydroxyapat-6-enoic acid | |
| HK1040924A1 (en) | Use of cholesterol-lowering agent | |
| TH68542A (en) | The use of cholesterol-lowering agents |